Adrenomedullin and Outcome in Severe Sepsis and Septic Shock
- Conditions
- Severe SepsisSeptic Shock
- Registration Number
- NCT02393781
- Lead Sponsor
- Sphingotec GmbH
- Brief Summary
The aim of this prospective study is to assess the prognostic value of bioactive plasma adrenomedullin (ADM) in 600 patients with severe sepsis or septic shock in an international multicenter study and to validate the findings concerning the association of ADM concentration and the use of vasopressor therapy, organ failure and outcome.
- Detailed Description
Sepsis involves an overactive inflammatory response to severe bacterial infection that can compromise vascular integrity and cause tissue edema, organ dysfunction and death. Adrenomedullin (ADM) has attracted the interest of researchers because of its powerful physiological functions. An anti-ADM antibody reduced the norepinephrine infusion rates required to achieve hemodynamic targets, increased urine flow and improved creatinine clearance, which ultimately resulted in attenuated systemic inflammation and tissue apoptosis, during resuscitated cecal ligation and puncture (CLP)-induced septic shock in mice.
In humans, plasma ADM has been determined only in a small number of sepsis patients, and - except from one study - the assays used did not selectively measure the bioactive ADM form and have been considered not reliable. Therefore, the potential value of determining plasma ADM in such patients cannot yet be ascertained and the optimal cut off needs to be validated in future studies
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 596
- Age >18 years
- Patients admitted in intensive care unit for severe sepsis or septic shock according to international, standardized criteria,transferred from another intensive care unit less than 24 hours after the primary admission, or being treated with vasopressors for less than 24 hours in the prior ICU
- Signed Consent form
- Age < 18 years
- Severe sepsis or septic shock patients transferred from another intensive care unit later than 24 hours after the primary admission or being treated with vasopressors for more than 24 hours in the prior ICU
- Pregnant women
- Vegetative coma
- Participation in an interventional clinical trial in the preceding month
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rate of all-cause mortality Day 28.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (24)
Cliniques Universitaires Saint-Luc
🇧🇪Brussels, Belgium
CHU Dupuytren
🇫🇷Limoges, France
CH Jolimont
🇧🇪La Louvière, Belgium
Hopital Estaing
🇫🇷Clermont-Ferrand, France
Nouvel Hôpital Civil
🇫🇷Strasbourg, France
Clinique St Pierre
🇧🇪Ottignies, Belgium
Centre Hospitalier d'Angers
🇫🇷Angers, France
Centre Hospitalier d'Angoulême
🇫🇷Angoulême, France
Hôpital Louis Mourier,
🇫🇷Colombes, France
Klinik für Operative Intensivmedizin und Intermediate Care
🇩🇪Aachen, Germany
CHD de la Vendée
🇫🇷La Roche Sur Yon, France
Hôpital St Louis
🇫🇷Paris, France
Hôpital Bichat Claude-Bernard
🇫🇷Paris, France
Hôpital Lariboisière
🇫🇷Paris, France
Policlinico Universitario A. Gemelli
🇮🇹Roma, Italy
CHRU Tours
🇫🇷Tours, France
Klinikum Augsburg
🇩🇪Augsburg, Germany
Klinik für Anästhesie, Intensivmedizin und Schmerztherapie, HELIOS-Klinikum Erfurt,
🇩🇪Erfurt, Germany
Klinik für Anästhesiologie und Operative Intensivmedizin, Universitätsklinikum Köln
🇩🇪Köln, Germany
Medisch Spectrum Twente; Departement of Intensive Care
🇳🇱Enschede, Netherlands
Azienda Ospedaliera Sant'Andrea
🇮🇹Roma, Italy
UMC Radboudziekenhuis, Dept. Intensive Care
🇳🇱Nijmegen, Netherlands
Hôpital de Hautepierre
🇫🇷Strasbourg, France
Universitätsklinikum Jena
🇩🇪Jena, Germany